Extended Aromatase Inhibitors in Hormone-Receptor–Positive Breast Cancer
Mené sur 3 484 patientes atteintes d'un cancer du sein HR+ après la ménopause, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de la prolongation, pendant 2 ou 5 années supplémentaires, d'un traitement adjuvant par inhibiteurs de l'aromatase
Advances in the diagnosis and adjuvant treatment of breast cancer have led to improved outcomes, with the large majority of women who have operable cancer today expected to be alive and recurrence-free in 5 years. However, women with hormone-receptor–positive breast cancer remain at constant annual risk of recurrence for at least 20 years after diagnosis.1 Researchers who are investigating the extension of adjuvant hormonal therapies beyond the typically prescribed 5 years — often involving aromatase inhibitors in postmenopausal women — have provided some evidence of benefit, particularly among women who received only tamoxifen during the first 5 years (...)